Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (11)

« Back to Publications

Structural basis for synergistic antibody protection against the essential malaria invasion complex protein RIPR

Williams BG. et al, (2025)

Cross reactive responses between filovirus species amongst a cohort of Ebolavirus Zaire survivors in Guinea, West Africa

Jiwa Y. et al, (2024), EUROPEAN JOURNAL OF IMMUNOLOGY, 54, 82 - 82

A review of broadly protective monoclonal antibodies to treat Ebola virus disease.

Rijal P. and Donnellan FR., (2023), Curr Opin Virol, 61

Identification and characterisation of candidate monoclonal antibody Ebolavirus therapeutics

Donnellan F., (2022)

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.

Ramasamy MN. et al, (2021), Lancet, 396, 1979 - 1993

The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 Beta (B.1.351) and other variants of concern in preclinical studies

Spencer AJ. et al, (2021)

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.

Barrett JR. et al, (2021), Nat Med, 27, 279 - 288

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

Voysey M. et al, (2021), Lancet, 397, 99 - 111

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.

Folegatti PM. et al, (2020), Lancet, 396, 467 - 478

Human Antibodies that Slow Erythrocyte Invasion Potentiate Malaria-Neutralizing Antibodies.

Alanine DGW. et al, (2019), Cell, 178, 216 - 228.e21

Therapeutic Monoclonal Antibodies for Ebola Virus Infection Derived from Vaccinated Humans.

Rijal P. et al, (2019), Cell Rep, 27, 172 - 186.e7